We are live on ! Find out more
LKFT icon

Lakefront Biotherapeutics American Depositary Shares

84 hedge funds and large institutions have $746M invested in Lakefront Biotherapeutics American Depositary Shares in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 21 increasing their positions, 34 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

245% more call options, than puts

Call options by funds: $6.94M | Put options by funds: $2.01M

1.88% less ownership

Funds ownership: 14.28% → 12.4% (-1.9%)

9% less funds holding

Funds holding: 92 → 84 (-8)

38% less repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 34

55% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 20

68% less capital inflows, than outflows

Capital inflows: $60.7M | Capital outflows: $190M

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
84
Holders Change
-8
Holders Change %
-8.7%
% of All Funds
1.87%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
9
Increased
21
Reduced
34
Closed
20
Calls
$6.94​M
Puts
$2.01​M
Net Calls
+$4.93​M
Net Calls Change
+$3.92​M

LKFT Hedge Fund Activity: Q4 2018 in Review

84 of the 4,504 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q4 2018, worth a combined $746M — down 30% from $1.06B a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of LKFT and 9 opened new positions — a net loss of 11 holders — while 34 trimmed existing stakes and 21 added.

The largest buyer was Bank of New York Mellon, adding an estimated $21.3M. The largest seller was OrbiMed, exiting entirely with an estimated $44M sold.

  • 84 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q4 2018, down from 92 in Q3 2018.
  • Funds reported $746M of Lakefront Biotherapeutics American Depositary Shares stock for Q4 2018, down 30% quarter-over-quarter.
  • 9 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q4 2018 and 20 closed out, a net change of -11 holders.
  • The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q4 2018 was Bank of New York Mellon, an estimated $21.3M added.
  • The largest Lakefront Biotherapeutics American Depositary Shares seller in Q4 2018 was OrbiMed, an estimated $44M sold.

Based on aggregated 13F filings for Q4 2018.